Loading viewer...
investor_presentation
Format: PDF investor_presentation
VYNE Therapeutics is developing proprietary therapies for immuno-inflammatory conditions, including atopic dermatitis and rare skin diseases. The company's pipeline includes JAK/sphingosine-1 receptor modulator combinations and BET inhibitors through its novel InhiBET platform, with multiple near-term catalysts across clinical candidates VYN201 and VYN202.
presentation
investor_presentation
12 Pages
Unknown
Sandy Spring Bancorp Q1 2021 Investor Presentation
investor_presentationinvestor_presentation
41 Pages
Sandy Spring Bancorp, Inc.